jain.com

Q3 2026 capital expenditure guidance

Company: Nebius

Subject kind
guidance
Statement date
2026-09-21
Promised by
2026-09-30
Promised amount
11500000000.0 USD
Current status
outcome unconfirmed

What the later record shows

Outcome not yet confirmed

No passage reports actual Q3 2026 capital expenditure. The capital spending figures provided are for the first half of 2026 or an unspecified period.

Checked November 10, 2026 against filings, releases and reporting published after the claim was made. Quotes are verbatim from the linked documents.

The claim, verbatim

Expects to spend $11.5-13.5 billion on capital expenditure in Q3 2026

Source (primary)

Nebius vs. CoreWeave: Which AI Cloud Stock Is the Better Buy? - Yahoo Finance (-, news_article)
View cached copy (2026-09-23)Live source ↗

Quote: “It expects to spend $11.5-$13.5 billion on capital expenditure in the third quarter”

How we checked this

Checked on October 2, 2026. The cited source supports every part of this claim.

The article, published in September 2026 and discussing CoreWeave's 2026 guidance after its second-quarter results, states third-quarter capex guidance of $11.5-$13.5 billion.

Confirmed in the source:

What we did: Read our cached copy of the publisher (https://finance.yahoo.com/markets/stocks/articles/nebius-vs-coreweave-ai-cloud-144900272.html) in full (18,146 characters, retrieved September 23, 2026) and checked each assertion in the claim against it.

Additional evidence

confirms Nebius vs. CoreWeave: Which AI Cloud Stock Is the Better Buy? - Yahoo Finance

Quote: “It expects to spend $11.5-$13.5 billion on capital expenditure in the third quarter”

View cached copy (2026-09-23)Live source ↗

Record of changes

September 23, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
October 1, 2026 — outcome unconfirmed
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.